NO20052975L - Nye 2',5'-oligoadenylsyreanaloger. - Google Patents
Nye 2',5'-oligoadenylsyreanaloger.Info
- Publication number
- NO20052975L NO20052975L NO20052975A NO20052975A NO20052975L NO 20052975 L NO20052975 L NO 20052975L NO 20052975 A NO20052975 A NO 20052975A NO 20052975 A NO20052975 A NO 20052975A NO 20052975 L NO20052975 L NO 20052975L
- Authority
- NO
- Norway
- Prior art keywords
- optionally substituted
- mercapto
- nucleic acid
- synthesis
- blocked
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/319—Chemical structure of the backbone linked by 2'-5' linkages, i.e. having a free 3'-position
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
2-5A-analoger som har den generelle forme1 (1) og farmakologisk akseptable salter der-av: (1) hvor m er 0 eller 1; n er 0-2; R1 er eventuelt substituert C1-6-alkoksy, merkapto, merkapto blokkert med en beskyttelsesgruppe for syntese av nukleinsyre, eller eventuelt substituert C1-4-alkyltio; R2, R3, R4, R5 og R6 er hver hydroksyl, hydroksyl blokkert med en beskyttelsesgruppe for syntese av nukleinsyre, eventuelt substituert C1-6-alkoksy, merkapto, merkapto blokkert med en beskyttelsesgruppe for syntese av nukleinsyre, eller eventuelt substituert C1-4-alkyltio; R7 er oksygen eller -O(CH2CH2O)q- (hvor q er 2-6) ; R8 er hydrogen, eventuelt substituert C1-6-alkyl eller en 5'-fosforylert oligonukleotidanalog som mangier en hydroksylgruppe pa 5'-fosfatgruppen; og E1, E2, E3 og E4 er hver en naturlig eller modifisert nukleinsyreenhet.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002334731 | 2002-11-19 | ||
PCT/JP2003/014748 WO2004046161A1 (ja) | 2002-11-19 | 2003-11-19 | 新規2',5'-オリゴアデニル酸類縁体 |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20052975D0 NO20052975D0 (no) | 2005-06-17 |
NO20052975L true NO20052975L (no) | 2005-08-18 |
Family
ID=32321740
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20052975A NO20052975L (no) | 2002-11-19 | 2005-06-17 | Nye 2',5'-oligoadenylsyreanaloger. |
Country Status (17)
Country | Link |
---|---|
US (2) | US7651999B2 (no) |
EP (1) | EP1568704A4 (no) |
KR (1) | KR101117998B1 (no) |
CN (1) | CN1738829B (no) |
AU (1) | AU2003284578B2 (no) |
BR (1) | BR0316431A (no) |
CA (1) | CA2506581C (no) |
CO (1) | CO5690648A2 (no) |
IL (1) | IL168475A (no) |
MX (1) | MXPA05005321A (no) |
NO (1) | NO20052975L (no) |
NZ (1) | NZ539979A (no) |
PL (1) | PL211566B1 (no) |
RU (1) | RU2311422C2 (no) |
TW (1) | TWI347948B (no) |
WO (1) | WO2004046161A1 (no) |
ZA (1) | ZA200504017B (no) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020055479A1 (en) | 2000-01-18 | 2002-05-09 | Cowsert Lex M. | Antisense modulation of PTP1B expression |
US7179796B2 (en) | 2000-01-18 | 2007-02-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
TWI347948B (en) * | 2002-11-19 | 2011-09-01 | Sankyo Co | Novel 2',5'-oligoadenylic acid compositions |
US20050106101A1 (en) * | 2003-10-31 | 2005-05-19 | Ajay Purohit | Novel chemical agents comprising an adenosine moiety or an adenosine analog moiety and an imaging moiety and methods of their use |
KR101169179B1 (ko) * | 2005-05-18 | 2012-07-30 | 미쓰이 가가쿠 가부시키가이샤 | 올레핀 중합용 촉매, 올레핀 중합체의 제조방법, 프로필렌계 공중합체의 제조방법, 프로필렌 중합체, 프로필렌계 중합체 조성물 및 이들의 용도 |
MX2009008139A (es) * | 2007-01-31 | 2009-08-12 | Alios Biopharma Inc | Derivdos de 2-5a y su uso como agentes anti-cancer, antivirales y anti-parasitos. |
US20090181921A1 (en) * | 2007-12-21 | 2009-07-16 | Alios Biopharma Inc. | 2-5a analogs and their methods of use |
US20100009451A1 (en) * | 2008-05-30 | 2010-01-14 | Sigma Aldrich Company | Compositions and methods for specifically silencing a target nucleic acid |
US8658783B2 (en) | 2011-04-13 | 2014-02-25 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
ES2798301T3 (es) * | 2012-06-18 | 2020-12-10 | Daiichi Sankyo Co Ltd | Intermedio para producción de análogos de nucleósidos, y procedimiento para su producción |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0716856B1 (en) * | 1988-06-09 | 2001-08-29 | Temple University of the Commonwealth System of Higher Education | Therapeutic uses of 2',5'-oligoadenylate derivatives |
JP3781879B2 (ja) | 1996-11-18 | 2006-05-31 | 武 今西 | 新規ヌクレオチド類縁体 |
JP3756313B2 (ja) * | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
EP1152009B2 (en) * | 1999-02-12 | 2017-09-06 | Daiichi Sankyo Company, Limited | Novel nucleosides and oligonucleotide analogues |
AU1494801A (en) | 1999-09-29 | 2001-04-30 | Cleveland Clinic Foundation, The | Therapy with 2-5a and interferon |
JP4245837B2 (ja) * | 2000-12-21 | 2009-04-02 | 第一三共株式会社 | 2’,5’−オリゴアデニル酸類縁体 |
TWI347948B (en) * | 2002-11-19 | 2011-09-01 | Sankyo Co | Novel 2',5'-oligoadenylic acid compositions |
-
2003
- 2003-11-18 TW TW092132261A patent/TWI347948B/zh not_active IP Right Cessation
- 2003-11-19 KR KR1020057009011A patent/KR101117998B1/ko not_active IP Right Cessation
- 2003-11-19 AU AU2003284578A patent/AU2003284578B2/en not_active Ceased
- 2003-11-19 CA CA2506581A patent/CA2506581C/en not_active Expired - Fee Related
- 2003-11-19 RU RU2005115129/04A patent/RU2311422C2/ru not_active IP Right Cessation
- 2003-11-19 CN CN2003801089629A patent/CN1738829B/zh not_active Expired - Fee Related
- 2003-11-19 MX MXPA05005321A patent/MXPA05005321A/es active IP Right Grant
- 2003-11-19 PL PL376926A patent/PL211566B1/pl not_active IP Right Cessation
- 2003-11-19 EP EP03774061A patent/EP1568704A4/en not_active Withdrawn
- 2003-11-19 BR BR0316431-4A patent/BR0316431A/pt not_active IP Right Cessation
- 2003-11-19 NZ NZ539979A patent/NZ539979A/en not_active IP Right Cessation
- 2003-11-19 WO PCT/JP2003/014748 patent/WO2004046161A1/ja active IP Right Grant
-
2005
- 2005-05-09 IL IL168475A patent/IL168475A/en not_active IP Right Cessation
- 2005-05-16 US US11/131,412 patent/US7651999B2/en not_active Expired - Fee Related
- 2005-05-18 ZA ZA200504017A patent/ZA200504017B/en unknown
- 2005-05-18 CO CO05048112A patent/CO5690648A2/es unknown
- 2005-06-17 NO NO20052975A patent/NO20052975L/no not_active Application Discontinuation
-
2009
- 2009-10-09 US US12/587,608 patent/US7994152B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
KR20050083891A (ko) | 2005-08-26 |
BR0316431A (pt) | 2005-10-11 |
PL211566B1 (pl) | 2012-05-31 |
AU2003284578B2 (en) | 2007-07-05 |
NZ539979A (en) | 2007-05-31 |
CN1738829A (zh) | 2006-02-22 |
CO5690648A2 (es) | 2006-10-31 |
IL168475A (en) | 2010-05-31 |
RU2311422C2 (ru) | 2007-11-27 |
TWI347948B (en) | 2011-09-01 |
MXPA05005321A (es) | 2005-07-25 |
WO2004046161A1 (ja) | 2004-06-03 |
CA2506581A1 (en) | 2004-06-03 |
ZA200504017B (en) | 2006-02-22 |
US7994152B2 (en) | 2011-08-09 |
CN1738829B (zh) | 2012-11-28 |
RU2005115129A (ru) | 2006-02-27 |
CA2506581C (en) | 2013-05-28 |
EP1568704A4 (en) | 2009-12-02 |
US7651999B2 (en) | 2010-01-26 |
PL376926A1 (pl) | 2006-01-09 |
NO20052975D0 (no) | 2005-06-17 |
EP1568704A1 (en) | 2005-08-31 |
US20100035976A1 (en) | 2010-02-11 |
KR101117998B1 (ko) | 2012-04-12 |
US20050261235A1 (en) | 2005-11-24 |
AU2003284578A1 (en) | 2004-06-15 |
TW200416224A (en) | 2004-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20052975L (no) | Nye 2',5'-oligoadenylsyreanaloger. | |
HUP0105367A2 (hu) | Új nukleozid és oligonukleotid analogonok | |
HUP0101137A2 (hu) | Véralvadást gátló savamidin-származékok és gyógyászati alkalmazásuk | |
CL2004000917A1 (es) | Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa | |
WO2007118198A8 (en) | 2-METHYLENE-1α,25-DIHYDROXY-19,21-DINORVITAMIN D3 ANALOGS AND USES THEREOF | |
ECSP045229A (es) | Piridinonas sustituidas como moduladores de la p38 map quinasa | |
UA85583C2 (ru) | Применение ротиготина для профилактики и лечения синдрома паркинсона (плюс) | |
NO20006251L (no) | Benzotiepin-1,1-dioksidderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder disse forbindelsene og deres anvendelse | |
ATE277066T1 (de) | Bicyclonucleosid-analoga | |
UA84460C2 (ru) | Применение сульфонилкарбамидов для борьбы с нежелательным ростом растений в культурах бобовых | |
ECSP066383A (es) | Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias | |
BRPI0111222B8 (pt) | derivados fosfonados de glicopeptídeo. | |
BRPI0508047A (pt) | derivados de alquilpiperazina-e alquil-homopiperazina-carboxilatos, o respectivo preparo e a respectiva aplicação como inibidores da enzima faah | |
EA200701406A1 (ru) | Приемлемые для лечения вич соединения | |
BRPI0810719A8 (pt) | Inibidores da enzima diacilglicerol o-acetiltansferase tipo 1 | |
WO2008035207A3 (en) | 2-methylene-1alpha-hydroxy-19,21-dinorvitamin d3 analogs and uses thereof | |
BRPI0413353A (pt) | composição farmacêutica contendo droga solúvel em água | |
WO2015158317A8 (en) | Use of a l,3j5-triazin-2-yl phosphoramidate compound in the synthesis of sofosbuvir | |
BRPI0403979A (pt) | composições contendo oligossacarìdeos | |
DK1848442T3 (da) | 2-methylene-19-nor-(20s-24epi)-1alfa,25-dihydroxyvitamine-d2 | |
BR0307033A (pt) | ácidos 3-(imidazolil)-2-aminopropanóicos para o uso como inibidores tafi-a para o tratamento de doenças trombóticas | |
TW200745048A (en) | Novel benzimidazole and benzothiazole derivatives, preparation process therefor, application thereof as medicaments, pharmaceutical compositions and novel use especially as CMET inhibitors | |
TW200724131A (en) | Antibacterial 5,5'-disubstituted 3,3'-dialkoxy-2,2'-dihydroxy-1,1'-biphenyl compounds and related methods | |
DK1135401T3 (da) | Glycerylnucleotider, fremgangsmåder til deres fremstilling og deres anvendelse | |
ATE525386T1 (de) | 3'-ethynylcytidinderivat |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |